Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase III study of Roche's taspoglutide in type 2 diabetes meets primary endpoint

May 3, 2010

Novel SAPK1/JNK1 inhibitors identified by U.S. researchers

May 3, 2010

New company LipimetiX created to focus on lipid-lowering treatments

April 30, 2010

Diamyd Medical continues phase III trials of Diamyd in diabetes

April 29, 2010

BioCryst reports on phase IIa trial of BCX-4208 in patients with gout

April 29, 2010

Phase II data presented on pasireotide in Cushing's disease and acromegaly

April 29, 2010

Living Cell Technologies receives grant from JDRF for phase II DiabeCell trial

April 28, 2010

Santaris advances SPC-5001 into development to lower cholesterol

April 28, 2010

No endocrine safety concerns noted in phase II trials of ulipristal acetate for uterine fibroids

April 28, 2010

Greater HbA1c reductions with LY-2189265 in Hispanic patients with type 2 diabetes

April 28, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...